BridgeBio Pharma Inc. (NASDAQ: BBIO) announced the FDA has accepted its new drug application for BBP-418, an oral treatment for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE